BGN

DGAP-News: Allterco JSCo continues strong profitable growth in 9M 2021

Thursday, November 25, 2021 - 8:02pm

Sofia / Munich, 25 November 2021 - Allterco JSCo (ticker A4L / ISIN: BG1100003166) ("Allterco"), a provider of IoT and smart home products based in Sofia, Bulgaria, upheld its growth momentum in the 9-month period and achieved further increases in revenues and earnings.

Key Points: 
  • Sofia / Munich, 25 November 2021 - Allterco JSCo (ticker A4L / ISIN: BG1100003166) ("Allterco"), a provider of IoT and smart home products based in Sofia, Bulgaria, upheld its growth momentum in the 9-month period and achieved further increases in revenues and earnings.
  • With an equity ratio of 89.4% as of 30 September 2021, Allterco enjoys a solid balance sheet (31 December 2020: 86.5%).
  • Dimitar Dimitrov, CEO of Allterco JSCo: "The excellent results in the first nine months of 2021 encourage us to continue on the expansion course we have embarked upon.
  • Allterco JSCo is a technology holding company that stands for innovation through the development, manufacture, and distribution of high-quality IoT products.

Ben-Gurion University Researchers to Develop Novel Biological Treatment for Inflammatory Bowel Diseases

Wednesday, August 11, 2021 - 7:00am

BEER-SHEVA, Israel, Aug. 11, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBD) by sequestering inflammation-inducing molecules secreted by gut bacteria.

Key Points: 
  • BEER-SHEVA, Israel, Aug. 11, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBD) by sequestering inflammation-inducing molecules secreted by gut bacteria.
  • Several recent studies show that succinate acts as a pro-inflammatory metabolite, in particular driving inflammatory activity of macrophages.
  • "Current treatments for IBD include antibiotics, steroids and biological treatments aimed at inhibiting the activity of the immune system.
  • BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students.

Fibank Successfully Launched a Capital Increase Procedure

Friday, April 24, 2020 - 11:34am

The new shares will have an issue price of BGN 5, which means that upon full subscription of the issue the bank will increase its capital by BGN 200 million.

Key Points: 
  • The new shares will have an issue price of BGN 5, which means that upon full subscription of the issue the bank will increase its capital by BGN 200 million.
  • According to the terms set out in the Prospectus, the capital increase will be considered successful is at least 4 million new shares are subscribed.
  • Fibank will use the capital increase to ensure implementation of its strategy to expand its market presence in retail banking and lending to small and medium-sized enterprises in Bulgaria.
  • As at the end of March, Fibank reported total capital adequacy ratio of 19.09%, Tier 1 capital ratio of 19.03% and CET1 capital ratio of 15.48%, with its regulatory capital reaching BGN 1,365 million.

Fibank Successfully Launched a Capital Increase Procedure

Friday, April 24, 2020 - 11:30am

The new shares will have an issue price of BGN 5, which means that upon full subscription of the issue the bank will increase its capital by BGN 200 million.

Key Points: 
  • The new shares will have an issue price of BGN 5, which means that upon full subscription of the issue the bank will increase its capital by BGN 200 million.
  • According to the terms set out in the Prospectus, the capital increase will be considered successful is at least 4 million new shares are subscribed.
  • Fibank will use the capital increase to ensure implementation of its strategy to expand its market presence in retail banking and lending to small and medium-sized enterprises in Bulgaria.
  • As at the end of March, Fibank reported total capital adequacy ratio of 19.09%, Tier 1 capital ratio of 19.03% and CET1 capital ratio of 15.48%, with its regulatory capital reaching BGN 1,365 million.

Fibank Ranks Among the Top 20 Banks in Southeast Europe for 2019

Wednesday, June 26, 2019 - 4:36pm

The bank's assets (consolidated) amounted to BGN 9.7 billion at the end of the first quarter of 2019, mainly driven by the strong lending activity.

Key Points: 
  • The bank's assets (consolidated) amounted to BGN 9.7 billion at the end of the first quarter of 2019, mainly driven by the strong lending activity.
  • Fibank also continues to be among the preferred banks by depositors in Bulgaria.
  • The consolidated pre-tax profit of Fibank (First Investment Bank) for the first quarter of 2019 increased by BGN 8.03 million YOY, reaching BGN 21.97 million.
  • Principal shareholders of Fibank are Mr. Ivailo Mutafchiev and Mr. Tseko Minev, together holding a total of 85% of the bank's equity.

Fibank Ranks Among the Top 20 Banks in Southeast Europe for 2019

Wednesday, June 26, 2019 - 4:31pm

The bank's assets (consolidated) amounted to BGN 9.7 billion at the end of the first quarter of 2019, mainly driven by the strong lending activity.

Key Points: 
  • The bank's assets (consolidated) amounted to BGN 9.7 billion at the end of the first quarter of 2019, mainly driven by the strong lending activity.
  • Fibank also continues to be among the preferred banks by depositors in Bulgaria.
  • The consolidated pre-tax profit of Fibank (First Investment Bank) for the first quarter of 2019 increased by BGN 8.03 million YOY, reaching BGN 21.97 million.
  • Principal shareholders of Fibank are Mr. Ivailo Mutafchiev and Mr. Tseko Minev, together holding a total of 85% of the bank's equity.